Candel Therapeutics

Historical price data

Candel Therapeutics is a clinical-stage biotech focused on developing multimodal oncolytic viral immunotherapies for cancer. Its mission is to leverage engineered adenovirus and herpes simplex virus (HSV) platforms to induce immunogenic cell death and train the immune system to fight tumors. The company's strategy centers on advancing its lead candidates, CAN-2409 and CAN-3110, through late-stage trials in non-small cell lung cancer (NSCLC), prostate cancer, pancreatic cancer, and brain cancer, aiming to generate pivotal data for regulatory submissions. As a publicly traded, pre-revenue entity, Candel's near-term value is tied to clinical milestones and partnership potential in the competitive immuno-oncology landscape.

Candel's technology is based on two engineered viral immunotherapy platforms: a replication-deficient adenovirus for localized gene delivery and prodrug activation (CAN-2409), and a replication-competent herpes simplex virus (HSV) designed for selective tumor lysis and immune stimulation (CAN-3110).

Candel competes with approved oncolytic viruses like Amgen's T-VEC and numerous clinical-stage biotechs developing viral and non-viral immunotherapies. Its key differentiators are the multimodal mechanism designed to induce a systemic immune response and the advancement of multiple programs into late-stage trials for large solid tumor indications.